Advanced search
Publication Cover
Hematology Volume 17, 2012 - Issue sup1
Submit an article Journal homepage
1,968
Views
14
CrossRef citations to date
0
Altmetric
Original Article

Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen

Morton ColemanCenter for Lymphoma and MyelomaWeill Cornell Medical College, The New York-Presbyterian Hospital, USACorrespondence[email protected]
,
Gia RuanCenter for Lymphoma and MyelomaWeill Cornell Medical College, The New York-Presbyterian Hospital, USA
,
Elstrom Rebecca L.Center for Lymphoma and MyelomaWeill Cornell Medical College, The New York-Presbyterian Hospital, USA
,
Peter MartinCenter for Lymphoma and MyelomaWeill Cornell Medical College, The New York-Presbyterian Hospital, USA
&
John P. LeonardCenter for Lymphoma and MyelomaWeill Cornell Medical College, The New York-Presbyterian Hospital, USA
Pages s90-s92 | Published online: 12 Nov 2013

References

  • Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, et al.. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008;112:2228–32.
  • Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, et al.. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma. 2008;49:447–50.
  • Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, et al.. Durable responses with the metronomic regimen RT-PEP-C in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010;116:2655–64.
  • Ruan J. Antiangiogenic therapies in non-Hodgkin’s lymphoma. Curr Cancer Drug Targets. Epub 2011 Sep 20.
  • Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–36.
  • Coleman M, Armitage JO, Gaynor M, McDermott D, Weisenburger DD, Adler K, et al.. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. Semin Hematol. 1988;25:23–33.
  • Coleman M, Martin P, Ruan R. The THRILL (thalidomide [T], rituximab [R], and lenalidomide [L]) regimen for chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma: daily alternating IMiDs and rituximab maintenance. J Clin Oncol. 2008;26:abstract 7079.
  • Kaufman H, Rederer M, Wöhrer S, Püspök A, Bankier A, Zielinski C, et al.. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood. 2004;104:2269–71.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.